ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
 PMID: 26572102       2015       BMC infectious diseases
Table: F227L


  HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
 PMID: 26558396       2015       PloS one
Table: F227L


  Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
 PMID: 26107265       2015       PloS one
Result: Sixteen out of 23 (70%) had NNRTI mutations (Y181C/I/D: 10; K103N: 6; V106A/I: 3; Y188C/L: 2; K101Q/E: 2; M230L: 1; P225H: 1; A98G: 1; V108I: 1; F227L: 1; K238T: 1), and 10 had >1 NNRTI mutation.


  HIV-1 transmitted drug resistance and genetic diversity among patients from Piaui State, Northeast Brazil.
 PMID: 25649362       2015       Journal of medical virology
Abstract: Dual class resistance mutations to NRTI and NNRTI were observed: T215L (NRTI), Y188L (NNRTI) and T215N (NRTI), F227L (NNRTI).


  Early clinical response and presence of viral resistant minority variants: a proof of concept study.
 PMID: 25397504       2014       Journal of the International AIDS Society
Abstract: Single mutations E138K (two cases) and M184V in three distinct patients and V90I+G190E; M184V+A98S; Y215F+V118I+T215I; L210S+T215I+F227L; and A62V+D67G+K70N+188H in the remaining five subjects.


  Emergence of drug resistance in human immunodeficiency virus type 1 infected patients from pune, India, at the end of 12 months of first line antiretroviral therapy initiation.
 PMID: 25006528       2014       ISRN AIDS
Discussion: L100I, K101P, P225H, F227L, M230L, and K238T are secondary mutations that usually occur in combination with one of the primary NNRTI resistance mutations.


  Transmitted drug resistance to rilpivirine among antiretroviral-naive patients living with HIV from northern Poland.
 PMID: 24746180       2014       Journal of the International AIDS Society
Abstract: RPV-associated mutations were divided into RPV resistance mutations (K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L) according to the International AIDS Society-USA (IAS-USA) mutation list and variants potentially affecting RPV susceptibility (L100I, K101H/T, E138S, V179F/D/G/T, G190A/E/S, F227L and M230V) based on the


  HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.
 PMID: 24456757       2014       AIDS research and therapy
Table: F227L


  Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.
 PMID: 24009694       2013       PloS one
Table: F227L


  Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
 PMID: 23840622       2013       PloS one
Method: The following non-polymorphic ARV-selected mutations were classified as drug resistance mutations (DRM): (i) the NRTI resistance mutations M41L, A62V, K65RN, D67NG, T69D, T69 insertions, T69 deletion, K70REGQ, L74VI, V75MT, F77L, Y115F, F116Y, Q151M, M184VI, L210W, T215YFSDCIV, and K219QENR; (ii) the



Browser Board

 Co-occurred Entities




   Filtrator